MA-ELECTRA-VEHICLES
11.4.2022 08:02:11 CEST | Business Wire | Press release
On April 5, 2022, automotive industry leader Alexander (Alex) Hitzinger was appointed to the Board of Directors at Electra Vehicles, Inc. as an Independent Board Member. The appointment marks another critical milestone for the growing AI battery software startup as the company expands its expert roster of electric vehicle leaders from the transportation industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220410005015/en/
Hitzinger boasts an extensive engineering and leadership career where he led key autonomous and electric vehicle projects. His career began at Toyota as a development engineer before working in the Formula 1 world as Head of Formula 1 Development at Cosworth and Head of Advanced Technologies at Red Bull’s Formula 1 Team. His penchant for leading cutting edge automotive technology projects led him to serve as Technical Director for the three times victorious Porsche 919 at the 24 Hours of Le Mans and Head of Product Design at Apple for Project Titan before co-founding and serving as CEO at ARTEMIS, where he lead the creation of a visionary autonomous vehicle concept. Most recently, Hitzinger served as Senior Vice President of Autonomous Driving at VW Group and Member of the Executive Board VWN, where he was involved in the development of the ID Buzz. With more than 20 years of experience in the automotive and electric vehicle industries, Hitzinger begins a new phase of his career with the aim of supporting promising young companies with disruptive technologies as they enter the automotive and electric vehicle world stage.
“I am looking for outstanding companies, with industry leading technologies, where I can help the management in deriving a successful strategy for scaling the company and the technology. Electra Vehicles, Inc. is exactly this type of company,” says Hitzinger. “The electrification of transportation is in full swing, but in many areas of the technology stack, there are still outdated technologies deployed. Electra is closing one of these gaps with its sophisticated battery performance management, and therefore I couldn’t be happier about joining Electra’s Board of Directors.”
CEO and Co-founder of Electra Vehicles, Fabrizio Martini, expresses his delight at welcoming Hitzinger to the Board: “The Electra team is honored, proud, and glad to welcome on its Board of Directors an extraordinary visionary like Alex Hitzinger. Alex is a world-renowned expert and award-winning talent in the Mobility sector. His experience, knowledge, and vision will guide Electra Vehicles, Inc. to make a significant global impact. I am genuinely excited to start partnering with Alex to bring the most advanced ML/AI-based technology worldwide for battery management solutions in the marketplace to enhance today’s transition to electric transportation.”
About Electra Vehicles, Inc.
Electra Vehicles is a leading B2B AI software company headquartered in Boston, MA, USA with a presence in Italy that produces embedded and Cloud-connected software to optimize the performance of electric vehicle battery systems for range, lifetime, charging, and safety benefits. Electra’s onboard EVE-Ai™ 360 Adaptive Controls and Cloud-based EVE-Ai™ Fleet Analytics are software that provide battery system performance insights, battery-conscious driver recommendations, and intelligent charging control strategies based on a continuously updating Adaptive Cell Model, making Electra’s EVE-Ai™ a necessity for electrified applications worldwide. In 2021, Electra Vehicles, Inc. became a BlackBerry IVY Fund investee and is a proud member of the BlackBerry IVY ecosystem.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220410005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom